Infliximab Level

Test Code

36303

Preferred Specimen

Red Top

Patient Preparation
Collect immediately before next scheduled dose (trough specimen)

Minimum Volume

0.5 mL

Transport Temperature

Refrigerated (cold packs)

Specimen Stability

Room temperature: 48 hours
Refrigerated: 7 days
Frozen -20° C: 28 days
Frozen -70° C: 6 months

Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)

Moderate and gross hemolysis

Methodology
Chemiluminescent Immunoassay

FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

Setup Schedule

Set up: Mon, Tues, Thurs-Sat; Report available: 3-5 days

Reference Range

See Laboratory Report

Clinical Significance

Infliximab is a therapeutic monoclonal antibody with the ability to bind to tumor necrosis factor (TNF), an inflammatory cytokine, blocking its action. Infliximab is indicated for the treatment of Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, and juvenile idiopathic arthritis. Trough concentrations of infliximab correlate with the likelihood of clinical remission, but the role of routine monitoring is not clear. Target concentrations may depend on indication, induction vs. maintenance, dosing schedules, drug clearance, and other factors.

The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed. Any Profile/panel component may be ordered separately. Reflex tests are performed at an additional charge.